Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

por Capehorn, Matthew, Hallén, Nino, Baker-Knight, James, Glah, Divina, Hunt, Barnaby
Publicado 2021

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression

por Lingvay, Ildiko, Bauer, Robert, Baker-Knight, James, Lawson, Jack, Pratley, Richard
Publicado 2021

The Economic Burden of Insulin-Related Hypoglycemia in Spain

por Parekh, Witesh, Hoskins, Nicki, Baker-Knight, James, Ramirez de Arellano, Antonio, Mezquita Raya, Pedro
Publicado 2017

Erratum to: The Economic Burden of Insulin-Related Hypoglycemia in Spain

por Parekh, Witesh, Hoskins, Nicki, Baker-Knight, James, Ramirez de Arellano, Antonio, Mezquita Raya, Pedro
Publicado 2017

The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System

por Parekh, Witesh, Streeton, Sophie E., Baker-Knight, James, Montagnoli, Roberta, Nicoziani, Paolo, Marchesini, Giulio
Publicado 2018

Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China

por McEwan, Phil, Baker-Knight, James, Ásbjörnsdóttir, Björg, Yi, Yunni, Fox, Aimee, Wyn, Robin
Publicado 2022

The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs

por Kotsopoulos, Nikolaos, Connolly, Mark P., Willis, Michael, Nilsson, Andreas, Ericsson, Åsa, Baker‐Knight, James
Publicado 2022